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Abstract
OBJECTIVES: The aim of this study was to evaluate the long-term outcomes following the Ross procedure in young adults in our institution.
METHODS: All adult patients who received a Ross operation between 1991 and 2014 were included in the study. Survival analysis and re-
gression analysis were performed. Survival of the Ross cohort was compared with the age-, gender- and calendar year-matched general
population.
RESULTS: Three hundred-and-six patients (mean age: 41.7 ± 9.7, male: 74.8%, bicuspid aortic valve: 58.5%, valve stenosis: 68%) were
included in the analysis. There were 7 perioperative deaths (2.3%). Nine patients were lost to follow-up from hospital and completeness of
the follow-up was 94%. The median follow-up of the remaining 290 patients was 10.6 years. There were 21 late deaths of which only 3
were valve-related. The overall survival at 15 years since surgery is 88 ± 3% that is comparable with the matched population. Freedom from
valve-related deaths was 96.8 ± 2% at 16 years. Freedom from autograft and pulmonary homograft reoperation was 74.5 ± 4.3% at 16 years.
Preoperative aortic regurgitation was the only signiﬁcant predictor of autograft failure over time. Freedom from the combined end point
of bleeding/thromboembolism/endocarditis/reoperation was 69.2 ± 4% at 16 years. Perioperative mortality following reoperation was
2.6% and the autograft could be spared in 72% of reinterventions.
CONCLUSIONS: The Ross operation in young adults is associated with an excellent survival in the long term that is comparable with the
general population. Although there is a risk of reoperation, incidence of other valve-related events is very low. The use of pulmonary auto-
graft should be considered in any young adult patient requiring aortic valve replacement.
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INTRODUCTION
Aortic valve replacement with the pulmonary autograft, also known
as Ross procedure, consists in replacement of the diseased aortic
valve with the patient’s own pulmonary valve while the latter is
usually replaced by a pulmonary homograft. Supposedly, the auto-
graft is the closest substitute to the native valve in terms of physiology
and haemodynamic proﬁle, and has no need for anticoagulation
[1–3]. Despite these proposed advantages, the technical complexity
and the risk of reintervention over time of the autograft, the pulmon-
ary homograft or both [4], have limited its widespread use and the
procedure is rarely performed in the USA while it is conﬁned to
some centres of excellence in Europe and elsewhere [5].
The aim of this study is to evaluate more than 20 years of ex-
perience with the Ross procedure in our institution with particular
attention paid to the survival and the risk of valve-related compli-
cations over time.
MATERIALS ANDMETHODS
All adult patients (>18 years of age) who underwent the Ross oper-
ation between June 1991 and January 2014 at two hospitals
(Cliniques Universitaires Saint-Luc and Cliniques Universitaires
Mont-Godinne, Belgium) of the Catholic University of Louvain by
two senior surgeons (Jean Rubay and Gebrine El Khoury) were
included in this analysis. During this period, the Ross operation
was offered to all adult patients with an age up to 55 years requir-
ing aortic valve replacement. This procedure was also considered
for older patients (up to 60 years of age) who speciﬁcally asked
for. Contraindications to this procedure were anomalies of the
pulmonary valve detected on preoperative echocardiogram or at
intraoperative exploration, and signiﬁcant comorbidities such as
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morbid obesity and severe chronic obstructive pulmonary disease
that make a shorter operation more advisable. Pure aortic regurgi-
tation and a native bicuspid valve were not a contraindication.
After discussing the pros and cons of the Ross operation and of
conventional aortic valve replacement with either a mechanical or
a biological prosthesis, patient’s informed consent was obtained.
On average, about one-fourth of the eligible patients preferred a
valve replacement with prosthesis.
During the study period, both surgeons had a similar surgical
approach. The root and inclusion technique have been previously
described [6]. Since 2010, we routinely stabilize the autograft
through inclusion in a Gelweave Valsalva™ graft (Vascutek,
Inchinnan, UK). The technique of Valsalva inclusion has been pre-
viously described [7]. The right ventricular outﬂow tract (RVOT)
was reconstructed with a cryopreserved pulmonary homograft in
288 patients (94.1%) and with a stentless xenograft (Medtronic
Freestyle® tissue valve, Minneapolis, MN, USA) in 18 cases (5.9%)
due to homograft unavailability. Perioperative and postoperative
management were also similar in the two hospitals.
The clinical follow-up data were collected by a questionnaire
sent to all the patients. When the questionnaire was not returned or
incomplete, phone contact was made with the patient or the refer-
ring physician. Subsequent hospitalization and routine visit data
were collected from hospital records and cardiologists’ reports.
The follow-up time was calculated either to death or to the last
veriﬁed contact with the living patient. The follow-up time for
valve-related events was calculated until the last valid assessment
of these complications. For the purpose of the study, the follow-
up period was closed in June 2014 as to have at least 6 months of
the potential follow-up for the last patients operated in 2013.
Completeness of the follow-up was calculated according to Clark
et al. [8]. Morbidity and mortality were reported according to the
2008 Society of Thoracic Surgeons/American Association for
Thoracic Surgery/European Association for Cardio-Thoracic Sur-
gery guidelines [9]. Early mortality was deﬁned as any death
occurring during hospital stay or during the ﬁrst 60 days after
the operation while any other death was considered a late death.
Clinical outcomes of interest included the incidence of systemic
embolism, bleeding event, endocarditis and reoperation on the
aortic or pulmonary valve for any cause. Reoperations were
deﬁned as reinterventions and catheter-based valve procedures
on the autograft or the RVOT substitute.
Statistical analysis
Continuous variables were reported as the mean ± SD for variables
with a normal distribution or as median and interquartile range
(IQR) for non-parametric distributions. Categorical variables were
reported as proportions. Survival was estimated with the life-table
method in order to compare with the expected survival of a
gender-, age- and calendar year-matched Belgian population
(estimated with the Conditional method (Ederer II) by means of
the mortality rates published by the Human Mortality Database
on www.mortality.org, accessed on 1 September 2014). Time-to-
event analysis was performed with the product-limit method
(Kaplan–Meier). A proportional hazard model (Cox regression)
was built to identify signiﬁcant predictors of reoperation on the
autograft or the RVOT substitute over time and predictors of late
death. The covariates to include into the ﬁnal model were selected
with a forward stepwise automatic procedure with a probability
of entry into the model of 0.15 and a probability of stay of 0.2.
Clinically meaningful covariates [age, body mass index (BMI), aeti-
ology of aortic valve disease, bicuspid valve, New York Heart
Association functional class, degree of aortic insufﬁciency, previ-
ous aortic valve procedure, predominant form of valve disease
(regurgitation vs stenosis) and previous infective endocarditis] and
operative variables (use of homograft vs xenograft for RVOT sub-
stitute, associated procedures, technique of autograft implant-
ation) were considered for inclusion into the model. The
assumption of proportional hazard was checked through the
interaction of the candidate predictor with time. Difference in
freedom from reoperation on the pulmonary autograft for
patients with predominant aortic stenosis versus patients with pre-
dominant aortic insufﬁciency at the time of surgery was assessed
by means of the log-rank test.
Results were considered statistically signiﬁcant at a P-value of
≤0.05.
All analyses were conducted with STATA 11.2 (StataCorp LP,
College Station, TX, USA).
RESULTS
A total of 306 patients were included in the analysis. Patient char-
acteristics and intraoperative data are presented in Tables 1 and 2.
Table 1: Preoperative characteristics of Ross patients
n = 306
Mean age ± SD (years) 41.7 ± 9.7
Age group [n (%)]
<30 47 (15.4)
30–50 193 (63.1)
≥50 66 (21.5)
Male (%) 229 (74.8)
Predominant lesion (%)
Stenosis 208 (68)
Regurgitation 96 (31.3)
Unknown 2 (0.7)
Aetiology (%)
Bicuspid valve 179 (58.5)
Degenerative 48 (15.7)
Rheumatic 16 (5.2)
Infective endocarditis 25 (8.2)
Prosthetic valve dysfunction 24 (7.8)
Unknown 14 (4.6)
Previous aortic valve intervention (%) 28 (9.2)
Body mass index (kg/m2) (mean ± SD) 26.3 ± 4.7
Missing values 16 (5.2%)
NYHA functional class (%)
I 77 (25.1)
II 138 (45.1)
III 84 (27.5)
IV 6 (2)
Missing values 1 (0.3)
Grade of aortic regurgitation [n (%)]
0 77 (25.2)
I 50 (16.3)
II 65 (21.2)
III 99 (32.4)
IV 13 (4.2)
Missing values 2 (0.7)
Left ventricular ejection fraction (%)
≥50 175 (57.2)
31–49 9 (3)
≤30 0
Missing values 122 (39.8)
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Early mortality was 2.3% (n = 7). Causes of early death were as
follows: 3 cardiogenic shock, 1 respiratory failure, 1 multiorgan
failure, 1 haemorrhagic stroke, 1 sudden death.
Nine patients (3%) were lost to the follow-up after 60 days follow-
ing discharge from hospital. Most of these patients came from
abroad, and were referred to our centre for surgery only. The com-
pleteness of the follow-up for the remaining 290 patients was 94%.
The median duration of the follow-up was 10.6 years (IQR: 4.3–14.8
years) with a total cumulative follow-up of 2938 patient-years.
Long-term survival
There were 21 deaths (7.2%) during the follow-up with a lineari-
zed mortality rate of 0.7% patient-year. Three deaths were valve-
related (1 due to bacterial endocarditis of both the autograft
and the pulmonary homograft, 1 sudden unexplained death and 1
following reoperation on both the autograft and the pulmonary
homograft for late failure); 18 deaths were from non-cardiac
causes: 9 cancer, 4 infection, 3 alcoholic hepatic cirrhosis, 1 for
complications of Alzheimer’s disease and 1 trauma. Therefore,
freedom from valve-related deaths was 96.8 ± 2% at 16 years since
surgery.
Overall survival is depicted in Fig. 1 together with the expected
survival of the age-, gender- and calendar year-matched Belgian
population. The two curves start to diverge at 10 years since
surgery and the difference becomes statistically signiﬁcant at 15
years when the cumulative relative survival ratio (RSR) is 0.93 (95%
CI: 0.84–0.99). Cumulative RSR at 20 years after surgery is 0.87
(95% CI: 0.71–0.97). Nevertheless, multivariate Cox-regression
analysis failed to identify any signiﬁcant predictor of late death.
Valve-related complications
No patient presented valve thrombosis but systemic embolism or
major bleeding events occurred in 20 patients (6.9%) during the
follow-up: 10 stroke, 6 transient ischaemic attack and 4 bleeding, al-
though none of these events were fatal. The linearized rate of
thromboembolic/bleeding events was therefore 0.7% patient-year.
Three patients (1.03%) presented infective endocarditis (1 on
the autograft that underwent replacement, 1 on the pulmonary
homograft that was successfully treated with antibiotics and 1 on
both valves that died without surgery). The linearized rate of bac-
terial endocarditis was therefore 0.1% patient-year.
Reoperation
There were no early (during the same hospitalization) but 39
(13.4%) late aortic or pulmonary valve reoperation (28 on the
autograft, 3 on the pulmonary homograft and 8 on both valves)
for a linearized rate of autograft/pulmonary valve reintervention
of 1.4% patient-year. Median interval of reoperation was 9.1 years
(IQR: 5.3–13.4 years).
Indications for reoperations were as follows: severe aortic regur-
gitation (n = 20, associated with ascending aorta dilatation in 7
cases), root dilatation with varying degrees of aortic insufﬁciency
(n = 15), isolated pulmonary homograft stenosis (n = 2), endocardi-
tis (n = 1) and stenosis of the distal anastomosis of the pulmonary
homograft (n = 1). Concomitant moderate-to-severe pulmonary
regurgitation or stenosis was present in 8 cases.
The pulmonary autograft was repaired in 26 cases (72%) by
means of valve-sparing root replacement (14 reimplantation tech-
nique, 1 remodelling) or cusp repair (n = 11). Further, the autograft
was repaired in 14 (82%) out of 17 patients re-operated in our
centre. In the remaining 10 cases, the aortic valve was replaced by
a mechanical prosthesis (n = 4), Bentall operation (n = 2), aortic
homograft (n = 2), biological prosthesis (n = 1), stentless xenograft
(n = 1).
The pulmonary homograft was replaced by another homograft
in 7 cases and by a stentless xenograft in 2 cases. Percutaneous
transcatheter balloon dilatation of the pulmonary homograft and
enlargement of the pulmonary artery with a pericardial patch were
performed in 1 case each. Perioperative mortality at reinterven-
tion was 2.6% (n = 1).
Three patients underwent a second valve reoperation due
to recurrence of aortic regurgitation after autograft repair in 2
cases and following replacement with a homograft in 1 case.
Three more patients underwent 5 mitral valve replacements during
the follow-up.
Freedom from reoperation on the autograft and from reopera-
tion on the RVOT was 75.6 ± 4.3% and 90.5 ± 3.5%, respectively at
16 years. Nevertheless, freedom from autograft reoperation was
signiﬁcantly better for patients with predominant aortic valve
Table 2: Operative characteristics of Ross patients
n = 306
Operative technique [n (%)]
Sub-coronary implantation 7 (2.3)
Root 168 (54.9)
Inclusion 131 (42.8)
Cylinder 116 (37.9)
Graft 15 (4.9)
Mean cardiopulmonary bypass time ± SD (min) 163 ± 65
Mean cross-clamp time ± SD (min) 113 ± 56
Concomitant procedures [n (%)] 54 (17.7)
Mitral valve repair [n (%)] 22 (7.2)
CABG [n (%)] 16 (5.2)
Other [n (%)] 18 (5.9)
Figure 1: Long-term survival of the Ross cohort including those who underwent
autograft replacement during the follow-up (dashed line, with 95% CI of the
survival estimates) and that of the age-, gender- and calendar year-matched
general population (solid line).
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stenosis compared with patients with predominant insufﬁciency
at the time of surgery (Fig. 2A) (82.7 ± 5.1 vs 65.3 ± 7.6, P = 0.02).
Freedom from any valve (autograft or pulmonary homograft)
and from all cardiac reoperation were 74.5 ± 4.3% and 70.6 ± 4.5%,
respectively at 16 years. Nevertheless, freedom from autograft re-
placement was 92.0 ± 2.5% at 16 years. Freedom from the com-
bined end point of bleeding/thromboembolism/endocarditis and
reoperation was 69.2 ± 4% at 16 years (Fig. 2B).
Univariate Cox-regression analysis revealed aortic regurgitation
as predominant form of valve disease, and young age at operation
as signiﬁcantly associated with late autograft failure. Other covari-
ates including bicuspid aortic valve, previous aortic valve surgery,
gender and BMI were not signiﬁcantly correlated with autograft
failure. Nevertheless, at multivariate analysis only aortic regurgita-
tion was still signiﬁcantly associated with late autograft failure with
a hazard ratio (HR) of 2.02 (95% CI: 1.04–3.94). The technique of
autograft implantation (root vs inclusion) is not associated with
the risk of late failure.
Signiﬁcant risk factors for RVOT substitute reoperation over
time are previous endocarditis (HR: 8.5, 95% CI: 1.7–43.9), younger
age at operation (HR: 0.9, 95% CI: 0.82–0.99) and BMI (kg/m2)
(HR: 1.13, 95% CI: 1.01–1.26). The use of pulmonary homograft vs
stentless xenograft is not associated with risk of late RVOT
reoperation.
Echocardiographic studies
Two hundred and ﬁfteen patients (85.7%) out of 251 who did not
require reoperation on the autograft/RVOT substitute had a trans-
thoracic echocardiogram at a median follow-up of 9 years (IQR:
4–13 years). At last available echo, 188 patients (87.4%) had none
or mild (<2+/4) aortic insufﬁciency (AI) while 27 (12.5%) presented
≥2 AI. Notably, only 1 patient had a 3+ AI and none had severe AI.
Further, 21 patients (9.8%) presented ≥2+ pulmonary homograft
regurgitation and only 7 patients (3.3%) presented a peak gradient
through the pulmonary homograft >40 mmHg.
DISCUSSION
The choice of a valve substitute for aortic valve replacement in
young adults (<60 years of age) can be particularly challenging. On
the one hand, a bioprosthetic valve, whether stented or homograft,
has been associated with over 50% risk of reoperation at 15 years
with the highest risk of reoperation in patients less than 40 years of
age [10, 11]. On the other hand, mechanical prostheses have a low
risk of reoperation but carry a signiﬁcant risk of valve-related com-
plications in the long-term, namely bleeding and thromboembolic
events. With both types of valve prostheses, long-term survival is
lower than the expected survival of the age- and gender-matched
reference population [12–14].
Our analysis has revealed that aortic valve replacement with the
pulmonary autograft is associated with 88 ± 3% survival at 15 years,
including those patients who required reoperation during the
follow-up which although different well compares to that of the
general matched population. It is also noteworthy that the whole
cohort showed an excellent survival despite the fact that 9.2% of
patients had had a previous aortic valve procedure and 12.4% of
patients had concomitant mitral or coronary surgery.
Previous reports [15–17] have observed a median survival at 15
years after the Ross operation of 93%, comparable to the age-
and sex-matched reference population. Difference in mean age at
operation (42 years in our series vs 36 in Andrea et al.’s and 34 in
David et al.’s series), in the mean follow-up (8 years in Andrea
et al.’s vs 10 years in ours) and nonetheless intrinsic differences in
the reference populations may account for this difference between
the series. Long-term survival in our cohort is also similar to that
reported by da Costa et al. [18].
Mokhles et al. [19] have shown in a propensity-score matched
analysis that survival after the Ross procedure and after mechanical
valve replacement were similar and were also comparable to that of
the general population. However, it must be noted that an import-
ant selection bias may affect the results of this study. On the one
hand, the Ross cohort was indeed a heterogeneous group of
patients included in the German-Dutch Ross Registry and coming
from 12 different centres with different expertise with the Ross
operation. On the other hand, the mechanical-aortic valve replace-
ment (m-AVR) patients came from a single centre, and were en-
rolled in the early self controlled anticoagulation trial II trial with
optimal anticoagulation self-management. Moreover, the mean
follow-up of Ross patients and m-AVR were only 5.1 and 6.3 years
Figure 2: (A) Kaplan–Meier curve representing the freedom from reoperation
on the autograft/RVOT substitute over time according to the predominant form
of aortic valve disease. (B) Kaplan–Meier curve representing the freedom from
the combined end point of major bleeding/systemic thromboembolism/endo-
carditis/reoperation on the autograft/RVOT. RVOT: right ventricular outﬂow
tract.
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respectively, which is too short a period to see a signiﬁcant differ-
ence in survival in a population of young patients. Furthermore,
Andreas et al. [20] have showed that in a real-world setting where
the oral anticoagulation of patients with a mechanical aortic valve is
managed by family doctors or laboratories, survival with the Ross
operation was signiﬁcantly better than m-AVR at 15 years (93 vs
75%) and was also comparable with that of the general population.
We consider the Ross operation a better option compared with
m-AVR in any young adult patient in the ‘real-world’ setting when-
ever aortic valve replacement is indicated. Regression analysis failed
to identify signiﬁcant predictors of late deaths but a very low inci-
dence of valve-related complications such as bleeding, thrombo-
embolism and infective endocarditis should be necessarily linked
to the improved survival of the Ross cohort. Incidence rates of
these complications in our series are also similar to the pooled esti-
mates of the meta-analysis by Takkemberg et al. [4]. However, it is
noteworthy that except for 1 case of endocarditis and 1 reoperation
on the autograft, these complications were never fatal.
The risk of reoperation on the autograft or the RVOT substitute
is a major objection to this procedure. Our series shows similar
results to previous reports [15, 18] in terms of long-term freedom
from valve reoperation but are signiﬁcantly lower than the results
reported by Charitos et al. [21] and David et al. [16]. Different
patient characteristics, aortic valve and root pathology, technique
of implantation of the autograft and nonetheless surgeon experi-
ence probably account for this discrepancy in the rate of reopera-
tion between the series. With a freedom from autograft/RVOT
substitute reoperation at 16 years of 75%, it means that 1 patient
out of 4 will need a reoperation before 20 years after the Ross
operation.
Similar to previous reports [16, 18, 19, 22, 23], our analysis con-
ﬁrms the association between preoperative aortic regurgitation
and late autograft failure, whereas the presence of a bicuspid valve
per se was not signiﬁcantly correlated with this negative outcome.
However, it should be noted that at present time pure aortic re-
gurgitation would be treated with valve-sparing techniques rather
than with the Ross procedure in our centre. Therefore as we have
currently adopted the Ross procedure only for eligible patients
with aortic stenosis, we may expect in the future a freedom from
reoperation on the autograft failure as high as over 80% at 16
years after surgery. Moreover, we did not see any signiﬁcant im-
provement in the rate of late failure with the inclusion technique
compared with the root technique. As previously observed, the in-
clusion technique protects the autograft from late dilatation but
does not prevent the occurrence of leaﬂet prolapse [6]. A few
years ago, we have introduced the stabilization of the autograft
with the inclusion into a Gelweave Valsalva™ graft (Vascutek,
Inchinnan, UK) before root implantation. As we have previously
described [7], this is a simple procedure aimed at preventing
further dilatation of the autograft, and is simpler than the cylinder-
inclusion technique. Nevertheless, our experience with this tech-
nique is at this point still too limited to observe any signiﬁcant
difference compared with the cylinder-inclusion. A longer follow-
up is needed to ﬁgure out if this technical improvement is
associated with any signiﬁcant clinical beneﬁt. Although aortic re-
gurgitation is associated with a higher risk of failure compared with
aortic stenosis with a HR of 2.02, late autograft dilatation and failure
may occur also in patients with predominant stenosis. Therefore,
our practice is to support the autograft also in patients with
predominant stenosis every time we use the root technique.
The risk of reoperation on the RVOT substitute constitutes
the second major objection to this operation. Freedom from
reoperation on the RVOT was 90.5% at 16 years, in line with other
series [17, 19, 22]. Our multivariate analysis revealed age, BMI and
previous endocarditis as signiﬁcantly associated with the risk of
RVOT substitute failure over time whereas the type of RVOT substi-
tute was not. The role of young age on the degeneration of the
RVOT valve was observed also by Weimar et al. [17]. However, due
to the limited number of events on the RVOT, and the small
number of cases where a stentless xenograft was used, these esti-
mates should be considered with caution. Previous reports [24]
have indeed found a signiﬁcant risk of reoperation on the RVOT
associated with the use of stentless xenograft and therefore in our
current practice the homograft is the substitute of choice for
RVOT reconstruction. We also observed that only a minority of
patients who did not undergo reoperation presented signiﬁcant
pulmonary homograft regurgitation or stenosis at last available
echocardiogram. However, it must be noted that the median
follow-up echo in this subgroup was only 9 years. The longer echo
follow-up will give us more insight on the fate of the RVOT substi-
tute in the long term. Isolated RVOT reoperation occurred in <1%
of patients but up to one-fourth of patients who required reopera-
tion on the autograft also needed RVOT substitute replacement.
This supports the hypothesis that the underlying pathology rather
than the surgical technique of implantation is linked to the late
failure of this procedure. Therefore, further understanding of
the aortic pathology and patients’ selection may further improve
the late outcome of the Ross operation.
Nevertheless, perioperative mortality in reoperation was a rea-
sonable 2.6% and the autograft could be preserved with valve-
sparing procedures in over 70% of redo in our experience. Rate of
autograft repair was also similar between the root and the inclu-
sion technique. Although reoperation can be technically more
demanding in the presence of the Inclusion technique, we did not
observe an increased risk of major perioperative complications
following reoperation in the presence of this technique of im-
plantation. Therefore, freedom from valve replacement was a high
92% at 16 years, extending the scope of the autograft use. These
results are therefore signiﬁcantly better than any AVR with bio-
prostheses in young adults [2, 10, 14]. Further, survival of patients
who required reoperation was not signiﬁcantly different at 16 years
compared with those who did not. Finally, although the use of
combined end points is debatable because they give the same
weight to events of different nature and with variable impact on
patient health, our analysis shows a freedom from the combined
end point of around 70% at 16 years or, in other words, that over
two-thirds of patients have not experienced any adverse
valve-related event since the operation.
Study limitations
Our study has several limitations that should be taken into
account. Although our patients were prospectively followed in our
centre, their long-term medical treatment was managed mainly
by their referring physicians. Therefore, differences in individual
treatment and lack of standardization may have an impact on the
outcomes that is unknown. In addition, echocardiographic follow-
up was not available in every patient and the median interval of
the last available scan was below 10 years. We cannot exclude that
some patients, although asymptomatic, may have autograft or pul-
monary homograft dysfunction. Finally, the limited number of
patients and of adverse events precludes any robust statistical ana-
lysis for the identiﬁcation of signiﬁcant predictors of failure.
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CONCLUSIONS
In conclusion, our study shows that the Ross operation is associated
with an excellent survival at 15 years that is comparable with the
matched general population. Although there is a signiﬁcant risk of
failure and need for reoperation, however due to a very low rate of
valve-related complications, the majority of patients will not experi-
ence any adverse events up to 15 years from surgery. The Ross op-
eration should be therefore considered, and discussed with every
young adult patient requiring aortic valve replacement.
Conﬂict of interest: none declared.
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APPENDIX. CONFERENCE DISCUSSION
Scan to your mobile or go to
http://www.oxfordjournals.org/page/6153/1
to search for the presentation on the EACTS library
Dr E. Charitos (Lübeck, Germany): The Brussels team is to be congratulated for
presenting their experience with over 300 young patients requiring a Ross pro-
cedure over the time course of 25 years. I have two questions and a small
comment.
One of the criticisms of the Ross procedure and the results of the Ross pro-
cedure has often to do with patient selection. The critique we see often is what
exactly drives the good results after the Ross procedure? Is it patient character-
istics or is it some beneﬁts of the autograft procedure? With this in mind, some-
times in order to evaluate the Ross procedure we need to study not only the
patients who received the Ross procedure but also the patients that did not. In
the absence of a randomized trial, this aims to investigate the role of patient
characteristics on the outcomes. During your 20-year experience, how many
patients, approximately, were screened or considered for the Ross procedure?
Do certain patient characteristics, haemodynamics, comorbidities or surgeon
preference play a role in selecting patients for the Ross procedure in your
cohort? With what criteria do you decide if a young patient will receive a Ross
procedure or a conventional aortic valve replacement? Perhaps you could elab-
orate a little bit on your patient selection process.
You also mentioned a small survival deviation in the Ross patients compared
to the general population, and in the manuscript you performed further sub-
group analysis investigating which age and gender subgroups has a relative
lower survival. We have to understand, however, that mortal events in young
individuals are rare events. On the other hand, cardiac and cardiac-related
morbidity and mortality are much more frequent in heart-operated patients
than in the general population. In that sense, one should not be surprised if the
survival of the Ross patients will at some point deviate from the general popula-
tion. This makes epidemiological sense. However, when and if the survival of
these patients deviates, it is important to know how much it deviates. All
studies until now show that the survival of the Ross patients is remarkably close
to the survival of the general population.
In your manuscript you do a further subgroup analysis. I personally ﬁnd the
subgroup analysis of 21 events in six further subgroups rather precarious for
formulating causal inferences. I am not sure if the ﬁnding that women between
30 and 50 years have a relative survival which is lower than that of the general
population is true, I don’t know if this ﬁnding is maybe a false positive ﬁnding.
Similarly, in the manuscript you mentioned that the xenografts in the right
ventricular outﬂow tract did not result in increased failure, and I think this should
be considered with caution. From the data from the Ross registry we see that the
hazard for reoperation with biological valves in the right ventricular outﬂow tract
is almost an order of magnitude higher than homograft. But in the manuscript
you rightly acknowledge that your study might be underpowered to investigate
the performance of xenografts in the right ventricular outﬂow tract.
My second question has to do with the fact that it is remarkable that you
could salvage almost 72% of the failing autografts with either a valve repair or a
valve-sparing technique. Have you observed any association between the ori-
ginal operative technique and the repairability in case of reoperation? Are
some techniques more repairable than others?
So my ﬁrst question has to do about your selection criteria for the Ross
procedure and the second question about the repairability of the various
techniques.
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Dr Mastrobuoni: Regarding patient selection, I can say that we are very
liberal. That means that we would screen every young patient that means above
18 and up to 50 years old, for these procedures. Even if a 56–57-year-old patient
comes for valve replacement in our centre, we would consider him for the Ross,
especially if the patient asks for it because he read about it on the Internet or
because his cardiologist told him, we would consider him for this procedure. So,
we would consider every young adult patient for the Ross procedure.
Of course, we have to also be realistic, and reviewing our analysis, for
example, of the patient who died early after the operation, I remember a lady
who was severely obese, with diabetes, hypertension, she was young, 45, but it
was a long procedure. So retrospectively I could say she was not the best candi-
date. So if you start doing it, of course, with a better patient selection, you
surely will have better results, as in everything.
So for our indication in a young patient whom we would consider, we will
discuss with the patient the pros and cons, the risk of reoperation but advan-
tages of not having oral anticoagulation and the low incidence of the related
complications.
So, as you said, of course, we had a few women in our series; 30% of our
patients were women. We did this group analysis, but, the numbers are limited.
Interestingly we found that the only subgroup where the survival diverged from
the expected survival was in women between 30 and 50. But again, the numbers
are very limited.
I totally agree with you that a guy that has been operated on the heart, I
don’t think it is realistic to expect a survival that is the same as a guy who has
not been operated on the heart. So, having a survival that is almost the same at
15 years, I think it is a very good result.
Regarding the pulmonary homograft, yes, we used the stentless xenograft in
a dozen patients, so the numbers are very limited, and we had only 11 reopera-
tions on the pulmonary homograft. So, we didn’t ﬁnd this a signiﬁcant risk
factor. Rather we found, young age of the recipient and BMI as a risk factor for
late pulmonary homograft failure, but again, the numbers are very limited to
have robust power.
And ﬁnally regarding the reoperation, we think that despite shifting from a
root to inclusion and now a vascular inclusion technique, the risk of reoperation
is about the same. What changes is the mechanism of late failure. We were able
to repair the autograft in our centre in over 80% of the cases. I think that prob-
ably with the inclusion technique the reoperation is a little bit more compli-
cated. However, we have a large experience in our centre on aortic root
surgery and aortic root reoperation, so it is not a big deal. But surely it is a little
bit more complicated.
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